NEW YORK (GenomeWeb News) - Clarient has acquired an exclusive license to Health Discovery Corporation’s prostate cancer marker and plans to develop and commercialize a test based on the marker, HDC said today.
 
Under the agreement, HDC will receive a 30 percent royalty payment for all prostate cancer tests Clarient performs for third parties using the technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.